Purchase Order 75N92022P00081
Award Date 3/1/22
Potential Completion Date 2/28/27
Potential Value $874K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a firm-fixed-price delivery order contract worth $247,444.82 to Illumina, Inc. to purchase sequencing reagent kits for the agency's Illumina NovaSeq 6000 and NextSeq 550 sequencing instruments. The contract has a completion date of September 2, 2025. Illumina is a manufacturer of genetic and genomic analysis instruments and...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases, a civilian agency within the U.S. Department of Health and Human Services, awarded a $999,999.00 firm fixed price purchase order to Illumina, Inc. to provide a NovaSeq X Plus sequencing system. This award is based on a September 2023 solicitation from the National Heart Lung and Blood Institute seeking a high-throughput DNA sequencing platform to support genomic research. The contract has no set-aside designation and a...
- The Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a firm-fixed-price delivery order to Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents, to purchase sequencing reagent kits for the agency's Illumina NovaSeq 6000 and NextSeq 2000 sequencers. The $202,227.89 award has a completion date of September 2, 2025 and does not utilize any set-aside designations....
- This firm fixed-price purchase order contract, awarded by the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH), provides Illumina, Inc. with a NovaSeq X Plus sequencing system to support genomic research initiatives. The $999,999.00 contract has a completion date of September 19, 2024. Illumina is a leading manufacturer of genetic sequencing and analysis technologies, and has been awarded numerous federal contracts and grants to supply sequencing...
- This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The $64,858.50 contract is for the provision of Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, along with accompanying reagents, consumables, sample preparation kits,...
- This is a firm fixed price delivery order awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a civilian agency, to Illumina, Inc. The order is for $75,832.10 and does not have a set-aside designation. Illumina, a manufacturer of genetic sequencing instruments and consumables, is providing products and services to support genomic sequencing and analysis, including NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, reagents, and bioinformatics support....
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a civilian agency, awarded a $24,104.50 firm fixed price purchase order contract to Illumina, Inc., a for-profit manufacturer of genetic sequencing and genomic analysis technologies. The contract, which does not have a set-aside designation, will provide the agency with Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing platforms, along with associated reagents, consumables, maintenance services, and...
- The Department of Health and Human Services National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a firm fixed price delivery order contract to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The $197,834.87 contract provides Illumina's NextSeq 2000 and 1000/2000 sequencing reagents to support life science research and diagnostics. This award is not associated with a set-aside program. Illumina has a history...
- Illumina, Inc. was awarded a firm fixed-price delivery order contract by the National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to provide sequencing reagent kits for the agency's Illumina NovaSeq 6000 and NextSeq 550 sequencing instruments. This $170,008.95 contract has a completion date of September 2, 2025 and will support the essential sequencing operations of NIAMS's Genomic Technology Section. Illumina is a manufacturer of...
- The Department of Health and Human Services National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a $75,014.08 firm fixed price delivery order contract to Illumina, Inc. of San Diego, California. The contract calls for Illumina to provide sequencing reagent kits for the agency's Illumina NovaSeq X Plus, NovaSeq 6000, and NextSeq 2000 sequencers to support its research efforts. No subcontractors or set aside designations were indicated. This...